SCHEMBL2274573

SCHEMBL2274573

N#Cc1cc(/C=C/C(=O)O)ccc1O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.64
HSD17B10 Q99714 3/20 0.64
CA12 O43570 3/20 0.64
CA1 P00915 3/20 0.64
CA2 P00918 3/20 0.64
CA3 P07451 3/20 0.64
CA4 P22748 3/20 0.64
CA6 P23280 3/20 0.64
CA5A P35218 3/20 0.64
CA7 P43166 3/20 0.64
CA9 Q16790 3/20 0.64
CA14 Q9ULX7 3/20 0.64
CA5B Q9Y2D0 3/20 0.64
AKR1B10 O60218 3/20 0.64
AKR1B1 P15121 3/20 0.64
ALDH1A1 P00352 3/20 0.64
DPP4 P27487 2/20 0.64
HPGD P15428 2/20 0.64
MAPK1 P28482 2/20 0.64
HDAC3 O15379 2/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4938529 1.00 KDM4E (0.64) KDM4EHSD17B10CA12CA1CA2
SCHEMBL6010547 0.87 KDM4E (0.64) KDM4EHSD17B10CA12CA1CA2
SCHEMBL8153863 0.86 KDM4E (0.56) KDM4EHSD17B10CA12CA1CA2
SCHEMBL8153860 0.86 KDM4E (0.56) KDM4EHSD17B10CA12CA1CA2
SCHEMBL922228 0.82 KDM4E (0.49) KDM4EHSD17B10CA12CA1CA2
SCHEMBL922227 0.82 KDM4E (0.49) KDM4EHSD17B10CA12CA1CA2
SCHEMBL19900021 0.82 KDM4E (0.49) KDM4EHSD17B10CA12CA1CA2
SCHEMBL19538090 0.81 APP (0.68) KDM4EHSD17B10CA12CA1CA2
Caffeic Acid SCHEMBL1172850 0.80 KDM4E (0.96) KDM4EHSD17B10CA12CA1CA2
Caffeic Acid SCHEMBL1172851 0.80 KDM4E (0.96) KDM4EHSD17B10CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023152218-A1 ANTIMICROBIAL SUSCEPTIBILITY FASTINOV, SA (PT) 2023-08-17 WO disclosed
CN-107636011-B Isolated peptides from fibrinogen and fragments thereof for use as medicaments, in particular in skin inflammatory diseases 巴黎笛卡尔大学 2021-07-02 CN disclosed
WO-2020225322-A1 ARGININE-BASED ANTIBACTERIAL POLYMERS WITH UCST PROPERTY CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2020-11-12 WO disclosed
US-20150352136-A1 NOVEL AMINOGLYCOSIDES AND USES THEREOF IN THE TREATMENT OF GENETIC DISORDERS TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2015-12-10 US disclosed
US-20150024955-A1 Methods of Identifying Modulators of Dephosphorylation of Histone Deacetylase THE J. DAVID GLADSTONE INSTITUTES 2015-01-22 US disclosed
EP-2751128-A2 CELL-PENETRATING PEPTIDES HAVING A CENTRAL HYDROPHOBIC DOMAIN Medical Research Council (GB) 2014-07-09 EP disclosed
US-20130312138-A1 PLANTS WITH INCREASED ACTIVITY OF A STARCH PHOSPHORYLATING ENZYME BAYER CROPSCIENCE AG (DE) 2013-11-21 US disclosed
WO-2013103780-A1 COMPOSITIONS AND METHODS TO BOOST ENDOGENOUS ROS PRODUCTION FROM BACTERIA TRUSTEES OF BOSTON UNIVERSITY (US) 2013-07-11 WO disclosed
WO-2013030569-A2 PEPTIDES GAIT MICHAEL JOHN (GB) 2013-03-07 WO disclosed
WO-2012166055-A1 METHOD FOR DETECTING DISEASE BIOMARKERS SINGAPORE HEALTH SERVICES PTE. LTD. (SG) 2012-12-06 WO disclosed
WO-2003044042-A1 SITE SELECTIVE ACYLATION MODPRO AB (SE) 2003-05-30 WO disclosed
EP-1250353-A2 P21 DERIVED PEPTIDES CAPABLE OF INHIBITING CDK/CYCLIN COMPLEXES Cyclacel Limited (GB) 2002-10-23 EP disclosed
WO-2000072004-A9 METHOD OF DETERMINING THE THREE-DIMENSIONAL SHAPE OF A MACROMOLECULE UNIV CALIFORNIA (US) 2002-08-29 WO disclosed
WO-2000023092-A9 CONTULAKIN-G, ANALOGS THEREOF AND USES THEREFOR COGNETIX INC (US) 2002-08-22 WO disclosed
US-20010014461-A1 Retentate chromatography and protein chip arrays with applications in biology and medicine CIPHERGEN BIOSYSTEMS, INC. 2001-08-16 US disclosed
WO-2001040142-A2 P21 DERIVED PEPTIDES CAPABLE OF INHIBITING CDK/CYCLIN COMPLEXES CYCLACEL LIMITED (GB) 2001-06-07 WO disclosed
EP-1086122-A1 PYRAZINONE PROTEASE INHIBITORS Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (US) 2001-03-28 EP disclosed
EP-0990256-A1 RETENTATE CHROMATOGRAPHY AND PROTEIN CHIP ARRAYS WITH APPLICATIONS IN BIOLOGY AND MEDICINE Ciphergen Biosystems, Inc. (US) 2000-04-05 EP disclosed
WO-1999064446-A1 PYRAZINONE PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 1999-12-16 WO disclosed
WO-1998059360-A1 RETENTATE CHROMATOGRAPHY AND PROTEIN CHIP ARRAYS WITH APPLICATIONS IN BIOLOGY AND MEDICINE CIPHERGEN BIOSYSTEMS, INC. (US) 1998-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150352136-A1 NOVEL AMINOGLYCOSIDES AND USES THEREOF IN THE TREATMENT OF GENETIC DISORDERS AARS1, NARS1, GOT1 KDM4E 3943/4885HSD17B10 1220/4885CA12 4731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.